The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets
Jessica K. Lee·Alexa B. Schrock·Kuei-Ting Chen·Bernard J. Fendler·Candice Francheska B. Tambaoan·Ryon P. Graf·Nicole Odzer·L. Pusztai·Maryam B. Lustberg·Harshabad Singh·Matthew R. Strickland·Tess A. O’Meara·Sara M. Tolaney·Timothy A. Yap·Jeffrey Ross·Amaya Gascó Hernández·Brennan Decker·Richard S.P. Huang·Samuel J. Klempner·Ethan S. Sokol·Julia C. F. Quintanilha
CN amplifications are prevalent and diverse biomarkers and AmpRatio is variable across genes and tumor types. ERBB2 AmpRatio is associated with outcomes to HER2-directed therapies and may have utility alongside IHC for clinical decision making. With the increasing number of therapies targeting amplifications/overexpression, it will be important to define harmonized methods for CN quantification for optimal patient selection.